Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

NCT01550744 is registered in ClinicalTrials.gov with Janssen Biotech, Inc. as lead sponsor.

NCT NCT01550744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01550744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
Lead sponsor
Janssen Biotech, Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2012
Completion date
July 31, 2015
Enrollment
478 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis